Lisinopril clinical laboratory findings

## Contents

* 1 Serum Electrolytes
* 2 Creatinine, Blood Urea Nitrogen
* 3 Hemoglobin and Hematocrit
* 4 Liver Function Tests

## Serum Electrolytes

[edit | edit source]

Hyperkalemia, hyponatremia.

## Creatinine, Blood Urea Nitrogen

[edit | edit source]

Minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of therapy, were observed in about 2% of patients with essential hypertension treated with lisinopril alone. Increases were more common in patients receiving concomitant diuretics and in patients with renal artery stenosis. Reversible minor increases in blood urea nitrogen and serum creatinine were observed in approximately 11.6% of patients with heart failure on concomitant diuretic therapy. Frequently, these abnormalities resolved when the dosage of the diuretic was decreased.

## Hemoglobin and Hematocrit

[edit | edit source]

Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.4 g% and 1.3 vol %, respectively) occurred frequently in patients treated with lisinopril but were rarely of clinical importance in patients without some other cause of anemia. In clinical trials, less than 0.1% of patients discontinued therapy due to anemia. Hemolytic anemia has been reported; a causal relationship to lisinopril cannot be excluded.

## Liver Function Tests

[edit | edit source]

Rarely, elevations of liver enzymes and/or serum bilirubin have occurred. In hypertensive patients, 2% discontinued therapy due to laboratory adverse experiences, principally elevations in blood urea nitrogen (0.6%), serum creatinine (0.5%) and serum potassium (0.4%).

In the heart failure trials, 3.4% of patients discontinued therapy due to laboratory adverse experiences; 1.8% due to elevations in blood urea nitrogen and/or creatinine and 0.6% due to elevations in serum potassium.

In the myocardial infarction trial, 2% of patients receiving lisinopril discontinued therapy due to renal dysfunction (increasing creatinine concentration to over 3 mg/dL or a doubling or more of the baseline serum creatinine concentration); less than 1% of patients discontinued therapy due to other laboratory adverse experiences: 0.1% with hyperkalemia and less than 0.1% with hepatic enzyme alterations.